Terns Pharmaceuticals, Inc. TERN 深 滬
已收盤 08-08 16:00:00 美东时间
6.08
+0.440
+7.80%
華盛通- 最 高6.1985
- 今 開5.67
- 成交量 79.90万股
- 最 低 5.635
- 昨 收 5.64
- 總市值 5.31亿
- 52周最高 11.40
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 1.865
- 委 比 8.45%
- 總股本 8733.78万
- 歷史最高 28.36
- 量 比 0.62
- 振 幅 9.99%
- 歷史最低 1.45
- 每 手 1
- 風險率 2.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.
08-07 21:55
WESTERN MIDSTREAM ANNOUNCES SECOND-QUARTER 2025 RESULTS
EXECUTING ON CORE GROWTH STRATEGY AND REAFFIRMING 2025 FINANCIAL GUIDANCE RANGES Reported second-quarter 2025 Net income attributable to limited partners of $333.8 million, generating record...
08-07 04:07
WESTERN MIDSTREAM TO ACQUIRE ARIS WATER SOLUTIONS
Creates a differentiated Delaware Basin produced-water system, enhancing WES's ability to compete for new business development opportunities. The combined infrastructure creates a fully inte...
08-07 04:05
Terns Pharma Q2 EPS $(0.26) Beats $(0.30) Estimate
Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 12.46 percent. This is a 16.13 percent increase over losses of $(0.31) per share from the
08-06 04:33
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Terns Pharmaceuticals reported Q2 2025 financial results and updates, highlighting progress in its CML and obesity programs. The Phase 1 CARDINAL trial for TERN-701 in CML is enrolling well, with 6-month major molecular response data expected in Q4. The Phase 2 FALCON trial for TERN-601 in obesity completed enrollment, with 12-week results anticipated in early Q4. The company has sufficient cash runway into 2028 to advance its CML program and see...
08-05 20:05
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc. has granted equity inducement awards to two new employees under its 2022 Employment Inducement Award Plan. Robin Andrulevich, the new Chief People Officer, and another non-executive employee received stock options to purchase 500,000 and 125,000 shares, respectively, with an exercise price of $5.47 per share. The options vest over four years and have a 10-year term. Terns is a clinical-stage biopharmaceutical company d...
08-04 20:05
WESTERN COPPER AND GOLD PROVIDES UPDATE ON ESE SUBMISSION
VANCOUVER, BC, July 15, 2025 /PRNewswire/ - Western Copper and Gold Corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) is pleased to provide an update on its Environmen...
07-15 19:30
Terns Pharma To Highlight Data From Completed Phase 1 Study Of TERN-601, Once-Daily Oral GLP-1R Agonist, At ADA Scientific Sessions
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected
06-24 04:09
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
Terns Pharmaceuticals announced data from the completed Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist, highlighting its differentiated profile among oral GLP-1R agonists. Key findings include statistically significant and dose-dependent weight loss of up to 5.5% over 28 days, efficient dose titration, and a favorable safety and tolerability profile. Phase 2 FALCON trial enrollment has been completed, with 12-week data expected...
06-23 20:07
Terns Pharmaceuticals Approves Directors and Accounting Firm
The latest update is out from Terns Pharmaceuticals ( ($TERN) ). On June 11, 20...
06-17 04:46
